Eli Lilly and Company (NYSE:LLY) Shares Sold by Raub Brock Capital Management LP

Raub Brock Capital Management LP lessened its stake in shares of Eli Lilly and Company (NYSE:LLY) by 3.0% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 23,879 shares of the company’s stock after selling 734 shares during the quarter. Eli Lilly and Company makes up 4.3% of Raub Brock Capital Management LP’s investment portfolio, making the stock its 9th biggest position. Raub Brock Capital Management LP’s holdings in Eli Lilly and Company were worth $21,156,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the company. Lynx Investment Advisory purchased a new stake in Eli Lilly and Company during the second quarter worth approximately $32,000. LGT Financial Advisors LLC acquired a new position in Eli Lilly and Company in the second quarter valued at $36,000. Redmont Wealth Advisors LLC acquired a new stake in Eli Lilly and Company during the 1st quarter worth approximately $40,000. Morton Brown Family Wealth LLC boosted its holdings in shares of Eli Lilly and Company by 45.5% in the second quarter. Morton Brown Family Wealth LLC now owns 48 shares of the company’s stock valued at $41,000 after acquiring an additional 15 shares in the last quarter. Finally, Cedar Mountain Advisors LLC increased its stake in shares of Eli Lilly and Company by 53.3% during the third quarter. Cedar Mountain Advisors LLC now owns 46 shares of the company’s stock worth $41,000 after acquiring an additional 16 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have issued reports on LLY. JPMorgan Chase & Co. boosted their target price on Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an “overweight” rating in a research report on Friday, September 13th. Sanford C. Bernstein started coverage on Eli Lilly and Company in a report on Thursday. They issued an “outperform” rating and a $1,100.00 target price for the company. Morgan Stanley reaffirmed an “overweight” rating and set a $1,106.00 price target on shares of Eli Lilly and Company in a research note on Tuesday, August 27th. Bank of America raised their price target on shares of Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a $1,025.00 price target on shares of Eli Lilly and Company in a report on Thursday, October 3rd. Three analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $986.00.

Eli Lilly and Company Trading Up 0.1 %

Eli Lilly and Company stock opened at $917.86 on Friday. Eli Lilly and Company has a 52-week low of $547.61 and a 52-week high of $972.53. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74. The firm has a market capitalization of $872.34 billion, a price-to-earnings ratio of 135.18, a PEG ratio of 2.79 and a beta of 0.42. The firm has a 50-day moving average price of $921.21 and a two-hundred day moving average price of $857.37.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.64 by $1.28. The business had revenue of $11.30 billion during the quarter, compared to analyst estimates of $9.83 billion. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. Sell-side analysts expect that Eli Lilly and Company will post 16.49 earnings per share for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.